A product containing carboxymethylcellulose, glycerin, and a preservative (Optive, Allergan), is a valuable option in the management of dry eye disease according to an open-label study evaluating patients who previously used an artificial tear product.
Topical cyclosporine 0.05% (Restasis, Allergan) limited progression or improved dry eye severity levels in most patients, while the use of artificial tears alone led to worsening of disease severity levels in nearly one-third of patients in a 12-month randomized study. The rapid progression of the disease in patients using artificial tears and the improvements in the patients using cyclosporine suggest that medication use could be beneficial for many individuals with level 2 dry eye disease.
A new artificial tear eye drop caused significantly less blurring on instillation than a control drop, and offers another option for the treatment of mild-to-moderate dry eye disease.
By implanting a punctal plug in both the superior and inferior punta-literally, plugging the drains-clinicians can reduce tear turnover rate via these ducts. Reducing nasolacrimal drainage is one way of increasing tear volume on the ocular surface, in the hopes of prolonging the residence time of the tear film, and thus improving the signs and symptoms of dry eye.
The eyes can be affected by over-the-counter (OTC) systemic medications, nutrition habits, and systemic agents-all of which contribute to dry eye. Oral treatment options should be considered in these cases, whereas topical treatment with artificial tears is the best option for external causes.
John Snisarenko, vice president of sales and marketing for Lucentis, outlines in an interview with Ophthalmology Times how Genentech Inc. is working to improve its relationship with the ophthalmic community as well as offer assistance to physicians and patients in accessing ranibizumab.
An unexpected appearance by the ailing Sen. Ted Kennedy (D-MA) helped secure bipartisan passage of a "veto-proof" bill to block a 10.6% pay cut for 600,000 physicians who treat Medicare patients. The bill, identical to a House version passed June 24, extends the 0.5% update through the end of 2008 and provides a 1.1% update to the conversion factor for 2009.
A fourth-generation version of the only accommodating IOL available in the United States has been approved by the FDA. The presbyopia-correcting implant (Crystalens HD, Bausch & Lomb) is built on the platform of the previous accommodating IOL and has a 5-mm optic but with a proprietary modification to improve depth of focus without degrading distance vision or contrast sensitivity.
The FDA has approved a new drug application for the topical ophthalmic corticosteroid difluprednate 0.05% emulsion (Durezol, Sirion Therapeutics) for four-times-daily dosing in the treatment of postoperative ocular inflammation and pain.
A 58-year-old Caucasian woman presented to the Bascom Palmer Eye Institute Emergency Department complaining of sudden loss of vision in the right eye 1 day prior. She denied pain or trauma to the right eye. Medical history was significant for poorly controlled type 2 diabetes mellitus, hypertension, hypercholesterolemia, and obesity.
The American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery are working with the American College of Physicians and the American Academy of Family Physicians to educate prescribers of tamsulosin (Flomax, Boehringer Ingelheim) about the association between the use of alpha blockers and intraoperative floppy eye syndrome.
Do pressure-independent factors play a role in glaucoma? That would seem to be the case, since the disease progresses in many patients despite IOP reduction. Enter a new line of thinking about the disease, neuroprotection, which was the topic of a symposium held here in conjunction with the World Ophthalmology Congress.
The newer generation of a dual-optic accommodating IOL (Synchrony, Visiogen) is easy to implant, centers well, provides good distance visual acuity, and demonstrates good safety in terms of potential posterior capsule opacification development, according to H. Burkhard Dick, MD.
Measuring the oxygen level of the retinal tissues may allow detection of retinal changes in patients with diabetes before structural changes in the capillaries occur, said Amani Fawzi, MD, Doheny Eye Institute, University of Southern California, Los Angeles.
The best results of surgery for the correction of congenital esotropia are achieved in children aged less than 12 months, according to Malcolm Ing, MD, chairman of the Division of Ophthalmology, University of Hawaii, Honolulu.
Adaptive optics scanning laser ophthalmoscope (SLO) imaging allows visualization of the minute details of the retina that were not visible previously and that can help explain visual disturbances, said Srinivas Sadda, MD, Doheny Eye Institute, University of Southern California, Los Angeles.
Patients who have masquerade syndromes-underlying disorders that present with signs and symptoms that appear to indicate idiopathic uveitis-are among the most challenging cases to ophthalmologists, said Scott Whitcup, MD.
Oral corticosteroid therapy is essential for ocular sarcoidosis. A sub-Tenon's triamcinolone infusion, however, is useful for older patients to avoid the side effects of corticosteroids. Managing ocular sarcoidosis often requires vitrectomy for fibrotic lesions and photocoagulation for ischemic retinopathy and macroaneurysms, said Nobuyuki Ohguro, MD, Osaka University Medical School, Osaka, Japan.
As new techniques in cataract surgery present so, too, do new complications and challenges in the management of such cases, said Gregg Kokame, MD, MMM, medical director of The Retina Center at Pali Momi, and clinical professor, Division of Ophthalmology, University of Hawaii School of Medicine, Honolulu.
There is much to be learned about nocturnal-and, more importantly, sleeping-IOP if ophthalmologists are going to optimize glaucoma therapies, said Yaniv Barkana, MD, Department of Ophthalmology, Assaf Harofeh Medical Center, Israel.
A new artificial iris implant (Dr. Schmidt Intraocularlinsen GmbH) provides patients with full or partial iris defects with good surgical results, such that it is difficult to differentiate the normal eye from the one that sustained trauma and underwent implantation of the artificial device.
The incidence of the development of cataracts is low after implantation of an implantable collamer lens (ICL), 1.96% over 5 years of follow-up. The common risk factors for cataract development in association with an ICL are patients aged more than 40 years, high myopia, surgeon learning curve, shallow anterior chamber depth, and male gender.
A technique for removing lens fragments that have fallen into the vitreous, developed by ophthalmologists in India, is a simple and effective surgical procedure, suggest results of a recent case series. The FAVIT technique was developed in 1999, and the recent series included cases performed with both a 900-μm phaco probe and a new modification, a 700-μm probe.
A study conducted in rabbit eyes showed that implantation of a hydrophilic IOL (Afinity Single Piece Collamer IOL, STAAR Surgical) presoaked in antibiotic may provide a method for delivering sustained, therapeutic intraocular concentrations of antibiotic following cataract surgery.
Wavefront aberrometry (ORange, WaveTec) used during cataract surgery seems to be an accurate tool for surgeons to predict postoperative visual outcomes. Intraoperative wavefront aberrometry may increase the accuracy of IOL power selection and help avoid postoperative refractive surprises.
A disposable pupil expansion device (Malyugin, MicroSurgical Technology) was evaluated in a series of 30 consecutive eyes of 21 patients taking tamsulosin (Flomax, Boehringer Ingelheim Pharmaceuticals) at the time of cataract surgery. The experience showed the device was easy to insert and remove. It maintained a 6.0-mm round pupil without causing significant iris trauma and allowed the surgeries to be completed without significant complications.
Micro transscleral pars plana vitrectomy using high-speed, 25-gauge instruments is an effective new way to handle an old challenge: performing phacoemulsification in patients with very shallow anterior chambers.
A polyethylene glycol-based ocular sealant is being developed as a synthetic bandage for clear corneal incisions to prevent wound gape, hypotony, and intraocular contamination. Preclinical and early clinical study results support its efficacy and safety.
A randomized, masked, clinical trial evaluated the integrity of phacoemulsification incisions by measuring ingress of ocular surface fluid using trypan blue as a quantifying tracer. The results favored use of either a 2.2-mm microcoaxial or 2.8-mm standard coaxial incision versus smaller bimanual incisions.
The internal controls and responsiveness to changes in vacuum with a new integrated phacoemulsification platform (Stellaris Vision Enhancement System, Bausch & Lomb) have made high-vacuum coaxial microincision surgery a safe and efficient procedure. The system also helps decrease the amount of excess energy added to the eye beyond what is needed to remove a cataract.
